AI Article Synopsis
- Elderly individuals (70 years and older) show weaker antibody responses to a COVID-19 booster compared to younger people after receiving an initial two-dose vaccine series with AZD1222 and a third mRNA booster.
- The elderly have a specific type of B cells (anomalous spike-specific B cells) that may impair their ability to neutralize the virus effectively after the booster.
- Interestingly, when elderly individuals receive three doses of mRNA vaccines, their antibody responses are comparable to those younger than 70, suggesting that different vaccine technologies influence immune memory formation.
Article Abstract
Suboptimal responses to a primary vaccination course have been reported in the elderly, but there is little information regarding the impact of age on responses to booster third doses. Here, we show that individuals 70 years or older (median age 73, range 70-75) who received a primary two-dose schedule with AZD1222 and booster third dose with mRNA vaccine achieve significantly lower neutralizing antibody responses against SARS-CoV-2 spike pseudotyped virus compared with those younger than 70 (median age 66, range 54-69) at 1 month post booster. Impaired neutralization potency and breadth post third dose in the elderly is associated with circulating "atypical" spike-specific B cells expressing CD11c and FCRL5. However, when considering individuals who received three doses of mRNA vaccine, we did not observe differences in neutralization or enrichment in atypical B cells. This work highlights the finding that AdV and mRNA COVID-19 vaccine formats differentially instruct the memory B cell response.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.celrep.2023.112991 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!